tbuckley/cabot-search huggingface dataset:
Abstract 143: Electrocardiographic Changes Preceding In-Hospital Cardiac Arrests From Pulseless Electrical Activity / Asystole Provide Insights into Underlying Cause and Pathophysiology
Authors: Jason J Yang, Duc H Do, Xiao Hu, Noel G Boyle
Journal: Circulation (2018)

Introduction: Survival from in-hospital cardiac arrests (IHCA) due to pulseless electrical activity (PEA) or asystole remains extremely poor. Our understanding of the pathophysiology of PEA is limited, and management of IHCA largely follows a “one size fits all” approach due to the lack of reliable methods to determine underlying cause in real-time. Hypothesis: Changes on continuous electrocardiogram (ECG) preceding IHCA reflect the underlying cause and pathophysiology of IHCA. Methods: We evaluated adult patients with IHCA from PEA/asystole at a tertiary care hospital between 3/2010 - 8/2014 with at least 3 hours of continuous ECG data preceding IHCA. We determined the likely cause of IHCA by reviewing of clinical, lab, imaging, and autopsy data. We analyzed up to 24 hours of continuous ECG data evaluating for changes in rhythm, PR interval, QRS and ST/T wave morphology leading up to IHCA. Results: Eighty-nine patients were studied (mean age 62 ± 18 years, 54% male). Return of spontaneous circulation was obtained in 65 (73%) and 24 (27%) survived to discharge. We found 5 distinct patterns of ECG changes leading up to and including the arrest rhythm (Table). Causes of cardiac arrest were significantly different between the group (Fischer’s exact p&lt;0.001). Notably, a severe right ventricular strain ECG pattern was found preceding PEA caused by pulmonary embolism, asphyxia from large mucus plugs or massive aspiration, acute respiratory distress syndrome, and cardiogenic shock with biventricular failure. Conclusion: Distinct patterns of changes in rhythm and ECG morphology which reflect different underlying causes and pathophysiology of IHCA were identified. Recognition of these patterns may provide an opportunity for better understanding of PEA mechanisms and outcomes, and allow for real-time prediction of IHCA cause to help direct management.
Another research probe for the brain
Journal: JAMA (1979)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.
Authors: Simon K.B. Spohn, Mark Gainey, Marius Kamps, Michael Mix, Juri Ruf, Matthias Benndorf, Sebastian Zschaeck, Pirus Ghadjar, Dimos Baltas, Anca L. Grosu, Constantinos Zamboglou
Journal: Journal of Clinical Oncology (2022)

260 Background: Positron emission tomography targeting prostate specific membrane antigen (PSMA-PET) changes treatment management of primary prostate cancer (PCa) patients and might improve focal dose escalation in radiotherapy (RT) due to superior coverage of intraprostatic tumour burden. The 2-armed, non-randomized HypoFocal phase II trial investigates the safety of implementation of PSMA-PET-based focal therapy planning in external beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT). Here we present results from the planned safety analysis after 6 months of follow-up (FU). Methods: Intermediate- and high risk PCa Patients with cN0 and cM0 staged by mpMRI and PSMA PET were included. EBRT was delivered in 20 fractions with 60 Gy to the prostate and up to 75 Gy to mpMRI- and PSMA-PET defined boost volumes (arm A). HDR-BT was delivered with 15 Gy to the prostate and a boost of up to 19 Gy, followed by EBRT with 44Gy in 20 fractions (arm B). 36% of patients received androgen deprivation therapy. Volumes, treatment plans, gastrointestinal (GI) and genitourinary (GU) toxicities according to CTCAE v5.0 and Quality of Life (QoL) was assessed. Results: 25 patients were enrolled in each study arm in two centers (Freiburg and Berlin). Clinical T stage was significantly different between mpMRI and PSMA-PET (p=0.007) with upstaging towards ≥ cT2c stages in PET. GTV-PET and GTV-Union were significantly larger than GTV-MRI, resulting in large boost volumes (see table). Boost volumes received a median mean dose of 70 Gy in EBRT and a median D90 of 19 Gy in HDR-BT At 6 months FU, prevalence of ≥ grade 2 GU and GI toxicity was 4% and 0% for arm A and 12 and 4% for arm B. Two patients experienced grade 3 GI toxicitiy 9 and 12 months after RT, related to biopsy. No signification change of QoL was observed after 6 months of FU. cT stages and target volumes. Conclusions: Implementation of PSMA-PET in primary PCa patients relevantly alters cT-stage and RT treatment management with significantly larger GTVs and subsequent boost volumes. Still, boost delivery was feasible with acceptable acute toxicities and good QoL. Putative oncological benefits should be evaluated in larger cohorts. Clinical trial information: DRKS00017570. [Table: see text]
Entry to Medical School: An Idle Hope
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Postmenopausal osteoporosis.
Authors: J C Stevenson, M I Whitehead
Journal: BMJ (1982)

aspergillosis, since full clinical and laboratory data are available on so few patients.Ketoconazole may prove useful as a prophy- lactic drug in severely immunosuppressed patients.In one re- cent study8 it was more effective than topical amphotericin B and nystatin in eliminating oral fungal carriage or infection in patients with leukaemia or marrow aplasia, with the exception of those receiving allogeneic bone marrow grafts.In clinical reports so far side effects such as nausea, head- ache, pruritus, and photophobia have been uncommon.Some recent reports have described probable hepatotoxicity.9Liver function values become transiently abnormal in some patients and symptomatic hepatitis (cholestatic or hepato- cellular) may occur in a very few patients.The incidence is probably less than one in 10 000,10 making it extremely difficult to establish a causal association; but clinicians using keto- conazole need to be aware of the possibility of liver damage with long-term treatment.Clearly, therefore, ketoconazole is going to be a useful drug for a wide variety of fungal infections, particularly dermato- phytosis, superficial candidiasis, and paracoccidioidomycosis.The response of most fungal infections to treatment varies considerably with the site of infection and the underlying condition of the patient.At present both the influence of these variables on the results of treatment with ketoconazole and the merits of the drug compared with effective alternatives are incompletely understood.The more detailed studies of keto- conazole currently in progress will help to establish its place in antifungal chemotherapy with greater precision.
Transactions of the American Association of Obstetricians and Gynecologists, Vol. ix.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 352: Predictive Value of Discharge Neurological Outcome Scores Following Out-of-Hospital Cardiac Arrest for Long-term Neurological Status: A Systematic Review
Authors: Wen Yu Wu, Amit Chopra, Shelley McLeod, Carolyn Ziegler, Steve Lin
Journal: Circulation (2018)

Introduction: Neurological outcomes following out-of-hospital cardiac arrest are commonly assessed using clinically validated outcome measures such as the Cerebral Performance Category (CPC) score, and are mainstay for evaluating neurological status at discharge. However, it remains unclear if these measures accurately reflect long-term neurological status after discharge. The primary objective of this systematic review was to better understand the predictive value of discharge neurological outcome scores for long-term neurological status. Methods: Comprehensive electronic searches of Medline, Embase and The Cochrane Library from inception to September 2016 were conducted and reference lists were hand-searched.Randomized controlled trials (RCT) and prospective observational studies were included. Our primary outcome was the correlation between discharge or 30 days post-arrest neurologic status and long-term ( &gt; 3 month) neurological outcome score. Preliminary Results: After screening 4,265 titles and abstracts independently and in duplicate, 6 studies including 5 prospective observational studies and 1 RCT were included. Four studies reported long-term follow-up at 6 months post-arrest and 2 studies reported follow-up at 1 year. In the studies with 6-month follow-up, 368/450 patients (82.7%) had favourable short-term neurological scores (CPC 1-2) at discharge or 30 days post-arrest, and 352/445 patients (79.1%) had favourable scores at 6 months post-arrest. In the studies with 1-year follow-up, 67/80 patients (83.8%) had favourable neurological scores at discharge or 30 days post-arrest, and 60/80 patients (75%) patients had favourable neurological scores at 1 year. Conclusion: Long-term neurological outcome scores following OHCA were consistent with short-term outcome at hospital discharge or 30 days post-arrest. Further studies are needed to elucidate more comprehensive prognostic factors for predicting long-term neurological outcome.
Issue Information
Authors: Carlo Brugnara, Stephen Ansell, Barbara Bain, Olivier Bernard, Anna Falanga, Shaji Kumar, Elizabeth Nemeth, David Porter, Ayalew Tefferi, Angela Weyand, Maureeen Achebe, Natasha Archer, Michael Auerbach, Pablo Bartolucci, Amy Bei, Joel Bennett, Ananda Prasad, Michelle Bayman, John Wiley, Joe Tomaszewski, Sheeba Martin, C Printers, Pte Ltd, San Parul Bhargava, Giada Francisco, Alessandra Biffi, Gautam Borthakur, Elisa Houston, Oh Cincinnati, Dario Bunn, Jorge Castillo, Daniela Cilloni, Jorge Cortes, Stacy Croteau, Corey Cutler, Lydie Da Costa, Paola Dal Cin, Courtney Boston, Houston Dinardo, Manoj Duraisingh, Elihu Estey, Guido Finazzi, Robert Fleming, Lucia Louis, Angela Dispenzieri, Deborah Elstein, Israel Jerusalem, Robert Boston, Letizia Louis, Paolo Foroni, Noelle Fortina, Peter Gaines, Frederic Galacteros, Patrick Gallagher, Guillermo Garcia-Manero, Beatrice Gee, Atlanta Ga, Saghi Ghaffari, New York, Mark Gladwin, Ivana Gojo, Jason Gotlib, Rachael Stanford, Jose Halperin, Jane Hankins, Elizabeth Hexner, John Higgins, Achille Iolascon, Elias Jabbour, Judith Houston, Eirini Karp, M Klimek, Marina Konopleva, Mark Houston, Robert Koury, Martha Lacy, Wilbur Lam, Francesco Lanza, Sophie Lanzkron, Mark Litzow, Alison Loren, Chris Lowrey, Franco Locatelli, Naomi Luban, Elisabet Manasanch, Mary Martin, Peter Marks, Anthony Mato, Janice Mcfarland, Christine Mclaren, Marc Michel, Caterina Minniti, Ann Mullally, Rakhi Naik, Valentina Nardi, Donna Neuberg, Ellis Boston, Bian Siok, Singapore Ng, Luigi Notarangelo, Enrico Novelli, Julie Panepinto, Animesh Pardanani, Melanie Percy, Alexander Perl, Elisa Piva, Olga Pozdnyakova, Rajiv Boston, Raffaele Pruthi, Linda Resar, Ran Reshef, Jean-Antoine Ribeil, Alicia Boston, Gail Rivera, New Roboz, Marco Ruggeri, Elisa Rumi, Vijay Sankaran, Giorgia Boston, Jodi Scapin, Dhvanit Segal, Akiko Shah, Amy Shimamura, Merav Sobota, Aliyah Socolovski, Martha Sohani, Martin Boston, Richard Steinberg, Jakub Stone, Marilyn Svoboda, Alberto Telen, Vicenza Tosetto, Italy Swee, Lay Thein, Venee Tubman, Lynne Houston, Celalettin Uhl, Srdan Ustun, Katja Houston, Stanford Weinacht, Olga Weinberg, Connie Westhoff, Clive Zent, Juan-Carlos Hernández-Boluda, Arturo Pereira, Nicolaus Kröger, Jan Cornelissen, Jürgen Finke, Dietrich Beelen, Moniek De Witte, Keith Wilson, Uwe Platzbecker, Henrik Sengeloev, Didier Blaise, Hermann Einsele, Katja Sockel, William Krüger, Stig Lenhoff, Adriano Salaroli, Hans Martin, Valentín García-Gutiérrez, Vicenzo Pavone, Alberto Alvarez-Larrán, José-María Raya, Katrin Tzarfati, Odit Gutwein, Arie Apel, Naomi Rahimi-Levene, Maya Sadovnik, Alessandro Broccoli, Lisa Argnani, Laura Nanni, Carolina Terragna, Elena Sabattini, Giulia Gabrielli, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Matteo Carella
Journal: American Journal of Hematology (2021)

10,651 (The Americas), US$11,067 (Rest of World), €7,145(Europe), £5,652 (UK).Prices are exclusive of tax.Asia-Pacific GST,
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
Authors: Dean A Fennell, Amy King, Seid Mohammed, Alastair Greystoke, Sarah Anthony, Charlotte Poile, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Anne Thomas, Dean A. Fennell, Amy King, Alastair Greystoke, Sarah Anthony, Sam Moody, Charlotte Poille, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G. Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Adrian Nicolson, Judith Underwood, Azmina Sodha-Ramdeen, Caroline Cowley, Shaun Barber, Anne Thomas
Journal: The Lancet Oncology (2022)
Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis
Authors: Guangbo Chen, Gail H. Deutsch, Grant S. Schulert, Hong Zheng, SoRi Jang, Bruce Trapnell, Pui Y. Lee, Claudia Macaubas, Katherine Ho, Corinne Schneider, Vivian E. Saper, Adriana Almeida de Jesus, Mark A. Krasnow, Alexei Grom, Raphaela Goldbach‐Mansky, Purvesh Khatri, Elizabeth D. Mellins, Scott W. Canna
Journal: Arthritis & Rheumatology (2022)

Objective Recent observations in systemic juvenile idiopathic arthritis (JIA) suggest an increasing incidence of high‐mortality interstitial lung disease often characterized by a variant of pulmonary alveolar proteinosis (PAP). Co‐occurrence of macrophage activation syndrome (MAS) and PAP in systemic JIA suggests a shared pathology, but patients with lung disease associated with systemic JIA (designated SJIA‐LD) also commonly experience features of drug reaction such as atypical rashes and eosinophilia. This study was undertaken to investigate immunopathology and identify biomarkers in systemic JIA, MAS, and SJIA‐LD. Methods We used SOMAscan to measure ~1,300 analytes in sera from healthy controls and patients with systemic JIA, MAS, SJIA‐LD, or other related diseases. We verified selected findings by enzyme‐linked immunosorbent assay and lung immunostaining. Because the proteome of a sample may reflect multiple states (systemic JIA, MAS, or SJIA‐LD), we used regression modeling to identify subsets of altered proteins associated with each state. We tested key findings in a validation cohort. Results Proteome alterations in active systemic JIA and MAS overlapped substantially, including known systemic JIA biomarkers such as serum amyloid A and S100A9, and novel elevations in the levels of heat‐shock proteins and glycolytic enzymes. Interleukin‐18 levels were elevated in all systemic JIA groups, particularly MAS and SJIA‐LD. We also identified an MAS‐independent SJIA‐LD signature notable for elevated levels of intercellular adhesion molecule 5 (ICAM‐5), matrix metalloproteinase 7 (MMP‐7), and allergic/eosinophilic chemokines, which have been previously associated with lung damage. Immunohistochemistry localized ICAM‐5 and MMP‐7 in the lungs of patients with SJIA‐LD. The ability of ICAM‐5 to distinguish SJIA‐LD from systemic JIA/MAS was independently validated. Conclusion Serum proteins support a systemic JIA–to‐MAS continuum; help distinguish systemic JIA, systemic JIA/MAS, and SJIA‐LD; and suggest etiologic hypotheses. Select biomarkers, such as ICAM‐5, could aid in early detection and management of SJIA‐LD.
Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).
Authors: Andrea Knox, Heidi Fettke, Christine Hauser, Patricia Bukczynska, Nicole Ng, Siavash Foroughi, Lisa-Jane K. Graham, Kate Lynette Mahon, Winston Tan, Tiantian Zheng, Chao Dai, Pan Du, Shidong Jia, Lisa Horvath, Manish Kohli, Arun Azad, Edmond Michael Kwan, Amy Wang
Journal: Journal of Clinical Oncology (2022)

150 Background: With the evolving use of targeted therapies exploiting genomic vulnerabilities in mCRPC, screening patients for sensitizing alterations is of increasing relevance. However, the influence of age on the detection of relevant genomic alterations is incompletely understood. In this study, we compared the cell-free DNA (cfDNA) profiles of younger (age &lt;70) versus older (age ≥70) men with mCRPC and assessed the relative prognostic impact of common genomic alterations. Methods: A next-generation sequencing-based Predicine cfDNA assay was used to profile 276 mCRPC patients from two independent international cohorts. The frequency of genomic alterations across age categories was compared using the chi-squared test, while circulating tumour DNA fraction (ctDNA%) was compared using the Mann–Whitney U test. Cox proportional hazards analysis with interaction testing was used to assess the association between age, genomic alteration and overall survival. Results: The median age of the combined cohort was 72 years (IQR 66-78), with 170 (62%) patients ≥70 years old. Despite differences in baseline characteristics (poorer performance status in older patients, higher Gleason score and de novo metastatic disease in younger patients), there was no significant difference in ctDNA% (median 22% vs 30%, p=0.6). We observed similar frequencies of genomic alterations across the 10 most commonly aberrant genes, including AR (&lt;70 vs ≥70: 46% vs 49%, p=0.6), TP53 (40% vs 36%, p=0.6), BRCA2 (29% vs 21%, p=0.13) and PTEN (39% vs 35%, p=0.5). This similarity persisted when analysing mutations and copy number alterations in isolation. While driver alterations in both age categories were strongly associated with unfavourable outcomes (Table), an exploratory analysis revealed that copy number gain in PIK3CA may have a worse prognostic impact in younger men ( p for interaction = 0.03), with a lesser effect observed in AR gain ( p = 0.1) and MYC gain ( p = 0.1). Conclusions: The genomic profiles of pertinent alterations between younger and older men are comparable. Certain genomic alterations may carry a worse prognosis in younger men. Patients should be considered for precision medicine assessment and directed therapies, regardless of age. [Table: see text]
Salop Infirmary
Authors: W. A. P. Dickin
Journal: BMJ (1858)

doses of opium, the hiccough became manifestly less, and gra- dually ceased.There was much less perspiration during the day.The pulse became regular, with more power.April 11th.He passed a good night; there was no hiccough, and very little perspiration.There was a little redness re- mair.ing about the stump, but no pain.He took no medicine, with the exception of one or two grains of opium at night.The stimulants were continued.April 15th.The leg and foot were still somewhat cedema- tous; the stump was nearly healed.He had had no return of hiccough, and slept without opium.The stimulants had been reduced to ten ounces of wine, and fifteen ounces of brandy.April 28th.He was progressing favourably, and had been able to get about the ward for some days, with the aid of crutches.The stimulants were reduced to four ounces of brandy, six ounces of wine, and one pint of bitter ale.May 20th.The stimulants had been gradually reduced to